Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.63 |
| ▸ | PAK4 | O96013 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | PRKCG | P05129 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.63 |
| ▸ | LYN | P07948 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.63 |
| ▸ | FER | P16591 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | FLT1 | P17948 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16336006 | 0.80 | BTK (1.00) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL29709483 | 0.80 | BTK (1.00) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL16338243 | 0.80 | BTK (0.71) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL16340450 | 0.80 | BTK (0.48) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL16382685 | 0.79 | BTK (0.48) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL6028389 | 0.79 | DHODH (0.59) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL16336471 | 0.79 | BTK (1.00) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL21008640 | 0.79 | BTK (0.60) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL29709597 | 0.79 | BTK (0.80) | BTKCHEK1PLK4DAPK3PRKD3 | |
| SCHEMBL16337965 | 0.79 | BTK (0.80) | BTKCHEK1PLK4DAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| CN-105530932-B | Primary formamide as BTK inhibitor | 艾伯维公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| EP-3483167-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3013337-B1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3013337-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | Abbvie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| CN-105530932-A | Primary carboxamides as BIK inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014210255-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | BTK 1/4885CHEK1 460/4885PLK4 1762/4885 |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | BTK 1/4885CHEK1 460/4885PLK4 1762/4885 |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | BTK 1/4885CHEK1 460/4885PLK4 1762/4885 |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | BTK 1/4885CHEK1 460/4885PLK4 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.